The below clickable headlines link directly to outside media outlets, which featured UNC School of Medicine faculty starting Friday, June 5, 2026.
Best Life: Miles from maternity care – Dr. Jeffrey Stringer (WMCTV)
HMN 2026: What is the promising new therapy for non-Hodgkin lymphoma – Dr. Blossom Damania (Health Medicine Network)
Bridge funds enable Carolina to continue diversity-targeted research – Dr. Audrey Pettifor (Watauga Democrat)
Physician experts call for systems-based approach to prostate cancer screening decisions – Dr. Adam Goldstein (Medical Xpress)
How AI is helping expectant moms who might be miles away from maternity care – Dr. Jefferey Stringer (WJXT)
The next goal for weight loss drugs? Fewer injections – Dr. John Buse (NBC News)
The next goal for weight loss drugs? Fewer injections – Dr. John Buse (MSN.com)
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide – Dr. John Buse (Yahoo! Finance)
It Takes a Village: Bringing Cell & Gene Therapy to Patients – J. Ryan Shaw, Tatjana Grgic, Rhianna Marusek, Rebecca Davis (Pharmacy Times)
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says – Dr. John Buse (Pharmacy Times)
Pivotal trial is recruiting for monthly GLP-1 for weight loss | ADA 2026 – Dr. John Buse (Managed Healthcare Executive)
‘Be Prepared?’ We’re Not When It Comes to PSA Testing – Dr. Adam Goldstein (Substack)
Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 Diabetes – Dr. Klara Klein (Associated Press)
Pfizer targets obesity market with monthly weight-loss injection data – Dr. John Buse (Yahoo! Finance)
Pfizer (PFE) Stock Gains Ground on Once-Monthly Obesity Drug Breakthrough – Dr. John Buse (CoinmarketCap)
Liver-Directed Insulin: A New Way to Reduce Hypoglycemia? – Dr. Klara Klein (Medscape)